Wiltshire HR[au] - Search Results

Year	Number of Results
1972	1
1975	1
1992	1
1997	2
1999	1
2000	2
2001	1
2002	1
2003	1
2005	1
2012	1
2022	0

1

A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.

Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. Wiltshire HR, et al. Anesth Analg. 2012 Aug;115(2):284-96. doi: 10.1213/ANE.0b013e318241f68a. Epub 2012 Jan 16. Anesth Analg. 2012. PMID: 22253270 Clinical Trial.

2

Modulation of oral squamous cell carcinoma incidence in rats via diet and a novel calcium channel antagonist.

Lenz B, Crameri FM, Eichler DA, Schläppi B, Wiltshire HR, Wood J, Seymour RA. Lenz B, et al. Among authors: wiltshire hr. Toxicol Pathol. 2005;33(3):356-64. doi: 10.1080/01926230590930119. Toxicol Pathol. 2005. PMID: 15805073

3

Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Smit JW, et al. Among authors: wiltshire hr. J Clin Invest. 1999 Nov;104(10):1441-7. doi: 10.1172/JCI7963. J Clin Invest. 1999. PMID: 10562306 Free PMC article.

4

The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.

Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF. Washington CB, et al. Among authors: wiltshire hr. Drug Metab Dispos. 2000 Sep;28(9):1058-62. Drug Metab Dispos. 2000. PMID: 10950849

5

Chromatographic and immunochemical approaches to the analysis of the HIV protease inhibitor saquinavir in plasma.

Wiltshire HR, Wiltshire BG, Clarke AF, Worth E, Prior KJ, Tjia JF. Wiltshire HR, et al. Anal Biochem. 2000 May 15;281(1):105-14. doi: 10.1006/abio.2000.4545. Anal Biochem. 2000. PMID: 10847617

6

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH. Huisman MT, et al. Among authors: wiltshire hr. J Pharmacol Exp Ther. 2003 Feb;304(2):596-602. doi: 10.1124/jpet.102.044388. J Pharmacol Exp Ther. 2003. PMID: 12538811

7

P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. Huisman MT, et al. Among authors: wiltshire hr. Mol Pharmacol. 2001 Apr;59(4):806-13. doi: 10.1124/mol.59.4.806. Mol Pharmacol. 2001. PMID: 11259625

8

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Huisman MT, et al. Among authors: wiltshire hr. AIDS. 2002 Nov 22;16(17):2295-301. doi: 10.1097/00002030-200211220-00009. AIDS. 2002. PMID: 12441801

9

Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man.

Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Madigan MJ, Sharp SR. Wiltshire HR, et al. Xenobiotica. 1997 Jun;27(6):539-56. doi: 10.1080/004982597240334. Xenobiotica. 1997. PMID: 9211655

10

Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man.

Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Harris SR, Worth E, Welker HA. Wiltshire HR, et al. Xenobiotica. 1997 Jun;27(6):557-71. doi: 10.1080/004982597240343. Xenobiotica. 1997. PMID: 9211656 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results